Sarecycline Hydrochloride Patent Expiration
Sarecycline Hydrochloride is Used for treating acne vulgaris in patients 9 years of age and older. It was first introduced by Almirall Llc
Sarecycline Hydrochloride Patents
Given below is the list of patents protecting Sarecycline Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Seysara | US8318706 | Substituted tetracycline compounds | May 01, 2031 | Almirall |
| Seysara | US8513223 | Substituted tetracycline compounds for treatment of inflammatory skin disorders | Dec 07, 2029 | Almirall |
| Seysara | US9255068 | Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same | Feb 09, 2033 | Almirall |
| Seysara | US9481639 | Substituted tetracycline compounds for treatment of inflammatory skin disorders | Aug 10, 2028 | Almirall |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Sarecycline Hydrochloride's patents.
Latest Legal Activities on Sarecycline Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Sarecycline Hydrochloride.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 May, 2024 | US8318706 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 May, 2024 | US9481639 |
| Requirement for information sent under 37 CFR 1.750 | 23 Jan, 2024 | US8318706 |
| transaction for FDA Determination of Regulatory Review Period | 28 Dec, 2023 | US8318706 |
| transaction for FDA Determination of Regulatory Review Period | 08 Dec, 2023 | US8318706 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jul, 2023 | US9255068 |
| Terminal Disclaimer Filed | 06 Dec, 2022 | US8318706 |
| PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED | 06 Dec, 2022 | US8318706 |
| Second letter to regulating agency to determine regulatory review period | 27 May, 2021 | US8318706 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Feb, 2021 | US8513223 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳